For citations:
Askarov V.E., Sultanbaev A.V., Menshikov K.V., Chalov V.S., Sultanbaeva N.I., Menshikova I.A. Combination BRAF/MEK Inhibitor Targeted Therapy and Immunotherapy (atezolizumab + vemurafenib + cobimetinib) for Metastatic Cutaneous Melanoma: Clinical Case. Creative surgery and oncology. 2025;15(2):171-178. (In Russ.) https://doi.org/10.24060/2076-3093-2025-15-2-75-82
Email this article 